{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:56:36Z","timestamp":1776387396129,"version":"3.51.2"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["294227"],"award-info":[{"award-number":["294227"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["294229"],"award-info":[{"award-number":["294229"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["307057"],"award-info":[{"award-number":["307057"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["311939"],"award-info":[{"award-number":["311939"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sigrid Juselius Foundation","award":["2015"],"award-info":[{"award-number":["2015"]}]},{"name":"Sigrid Juselius Foundation","award":["2016"],"award-info":[{"award-number":["2016"]}]},{"name":"Sigrid Juselius Foundation","award":["2017"],"award-info":[{"award-number":["2017"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.bioorg.2018.09.018","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T16:16:22Z","timestamp":1536682582000},"page":"494-503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Identification of human, rat and mouse hydrolyzing enzymes bioconverting amino acid ester prodrug of ketoprofen"],"prefix":"10.1016","volume":"81","author":[{"given":"K.M.","family":"Huttunen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2018.09.018_b0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","article-title":"The economic cost of brain disorders in Europe","volume":"19","author":"Olesen","year":"2012","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.bioorg.2018.09.018_b0010","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.neuron.2014.10.007","article-title":"Improving and accelerating drug development for nervous system disorders","volume":"84","author":"Pankevich","year":"2014","journal-title":"Neuron"},{"issue":"12","key":"10.1016\/j.bioorg.2018.09.018_b0015","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nrd4793","article-title":"Two decades of new drug development for central nervous system disorders","volume":"14","author":"Kesselheim","year":"2015","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"11","key":"10.1016\/j.bioorg.2018.09.018_b0020","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"21","key":"10.1016\/j.bioorg.2018.09.018_b0025","doi-asserted-by":"crossref","first-page":"12079","DOI":"10.1073\/pnas.96.21.12079","article-title":"Selective expression of the large neutral amino acid transporter at the blood-brain barrier","volume":"96","author":"Boado","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.bioorg.2018.09.018_b0030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/glia.21116","article-title":"Developmental and cell type-specific expression of thyroid hormone transporters in the mouse brain and in primary brain cells","volume":"59","author":"Braun","year":"2011","journal-title":"Glia"},{"issue":"4","key":"10.1016\/j.bioorg.2018.09.018_b0035","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1124\/mol.61.4.729","article-title":"Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition","volume":"61","author":"Uchino","year":"2002","journal-title":"Mol. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2018.09.018_b0040","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijpharm.2010.08.019","article-title":"Brain uptake of ketoprofen-lysine prodrug in rats","volume":"399","author":"Gynther","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.bioorg.2018.09.018_b0045","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1021\/acs.molpharmaceut.6b00217","article-title":"Systemic and brain pharmacokinetics of perforin inhibitor prodrugs","volume":"13","author":"Gynther","year":"2016","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.bioorg.2018.09.018_b0050","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s11095-012-0966-3","article-title":"Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine","volume":"30","author":"Peura","year":"2013","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2018.09.018_b0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijpharm.2015.12.034","article-title":"L-Type amino acid transporter 1 (lat1)-mediated targeted delivery of perforin inhibitors","volume":"498","author":"Huttunen","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioorg.2018.09.018_b0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2017.06.023","article-title":"L-type amino acid transporter 1 utilizing prodrugs: how to achieve effective brain delivery and low systemic exposure of drugs","volume":"261","author":"Puris","year":"2017","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.bioorg.2018.09.018_b0065","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s11064-016-1996-8","article-title":"Amino acid promoieties alter valproic acid pharmacokinetics and enable extended brain exposure","volume":"41","author":"Gynther","year":"2016","journal-title":"Neurochem. Res."},{"issue":"5","key":"10.1016\/j.bioorg.2018.09.018_b0070","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/jps.23942","article-title":"A novel strategy for ADME screening of prodrugs: combined use of serum and hepatocytes to integrate bioactivation and clearance, and predict exposure to both active and prodrug to the systemic circulation","volume":"103","author":"Hoppe","year":"2014","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.bioorg.2018.09.018_b0075","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/jps.20542","article-title":"Enzymes involved in the bioconversion of ester-based prodrugs","volume":"95","author":"Liederer","year":"2006","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2018.09.018_b0080","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2133\/dmpk.DMPK-12-RV-042","article-title":"The emerging role of human esterases","volume":"27","author":"Fukami","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.bioorg.2018.09.018_b0085","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/187231209788654081","article-title":"Esterase activities in the blood, liver and intestine of several preclinical species and humans","volume":"3","author":"Berry","year":"2009","journal-title":"Drug Metab. Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2018.09.018_b0090","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2006.07.001","article-title":"Structure, function and regulation of carboxylesterases","volume":"162","author":"Satoh","year":"2006","journal-title":"Chem. Biol. Interact."},{"issue":"4","key":"10.1016\/j.bioorg.2018.09.018_b0095","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1124\/dmd.111.043067","article-title":"Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse","volume":"40","author":"Kobayashi","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.bioorg.2018.09.018_b0100","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1194\/jlr.M400511-JLR200","article-title":"Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities","volume":"46","author":"Draganov","year":"2005","journal-title":"J. Lipid Res."},{"issue":"9","key":"10.1016\/j.bioorg.2018.09.018_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044598","article-title":"Readthrough acetylcholinesterase is increased in human liver cirrhosis","volume":"7","author":"Garcia-Ayllon","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bioorg.2018.09.018_b0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12291-012-0273-0","article-title":"Activity of hydrolytic enzymes in various regions of normal human brain tissue","volume":"28","author":"Prabha","year":"2013","journal-title":"Indian J. Clin. Biochem."},{"issue":"Pt B","key":"10.1016\/j.bioorg.2018.09.018_b0115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cbi.2016.05.036","article-title":"Paraoxonases-1, -2 and -3: what are their functions?","volume":"259","author":"Furlong","year":"2016","journal-title":"Chem. Biol. Interact."},{"issue":"4","key":"10.1016\/j.bioorg.2018.09.018_b0120","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1021\/jm701175d","article-title":"Large neutral amino acid transporter enables brain drug delivery via prodrugs","volume":"51","author":"Gynther","year":"2008","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2018.09.018_b0125","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1021\/acs.jmedchem.6b00190","article-title":"A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells","volume":"59","author":"Huttunen","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.018_b0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2014.11.019","article-title":"The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide","volume":"746","author":"Tollner","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2018.09.018_b0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejps.2015.07.006","article-title":"Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases","volume":"78","author":"Fukami","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2018.09.018_b0140","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1021\/jm0510124","article-title":"Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure","volume":"49","author":"Kumpulainen","year":"2006","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2018.09.018_b0145","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1021\/jm060394q","article-title":"Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system","volume":"49","author":"Saario","year":"2006","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2018.09.018_b0150","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/cmdc.201402281","article-title":"Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1)","volume":"9","author":"Ylikangas","year":"2014","journal-title":"ChemMedChem"},{"issue":"17","key":"10.1016\/j.bioorg.2018.09.018_b0155","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1002\/ejoc.201500361","article-title":"Mild Oxidative Cleavage of 9-BBN-Protected Amino Acid Derivatives","volume":"2015","author":"Ankner","year":"2015","journal-title":"Eur. J. Org. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2018.09.018_b0160","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2165\/00003088-200241100-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors","volume":"41","author":"Jann","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.bioorg.2018.09.018_b0165","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.bcp.2012.08.017","article-title":"Covalent inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597","volume":"84","author":"Crow","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.bioorg.2018.09.018_b0170","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1002\/jps.23258","article-title":"Species difference of esterase expression and hydrolase activity in plasma","volume":"101","author":"Bahar","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2018.09.018_b0175","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10517-011-1457-y","article-title":"Comparative analysis of esterase activities of human, mouse, and rat blood","volume":"152","author":"Rudakova","year":"2011","journal-title":"Bull. Exp. Biol. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2018.09.018_b0180","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.gene.2015.04.088","article-title":"Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles","volume":"567","author":"Mackness","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.bioorg.2018.09.018_b0185","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1746-6148-10-74","article-title":"Serum paraoxonase 1 (PON1) measurement: an update","volume":"10","author":"Ceron","year":"2014","journal-title":"BMC Vet. Res."},{"issue":"5","key":"10.1016\/j.bioorg.2018.09.018_b0190","first-page":"508","article-title":"In vitro inhibition of the paraoxonase from human serum with sulfonamide","volume":"7","author":"Sinan","year":"2008","journal-title":"Afr. J. Biotechnol."},{"key":"10.1016\/j.bioorg.2018.09.018_b0195","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/1875397300802010051","article-title":"A high throughput serum paraoxonase assay for discovery of small molecule modulators of PON1 activity","volume":"2","author":"Graves","year":"2008","journal-title":"Curr. Chem. Genom."},{"issue":"7","key":"10.1016\/j.bioorg.2018.09.018_b0200","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1124\/dmd.114.056994","article-title":"Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase","volume":"42","author":"Shimizu","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.bioorg.2018.09.018_b0205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2133\/dmpk.21.173","article-title":"Human carboxylesterase isozymes: catalytic properties and rational drug design","volume":"21","author":"Imai","year":"2006","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.bioorg.2018.09.018_b0210","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00129039-200212000-00015","article-title":"Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis","volume":"10","author":"Zhang","year":"2002","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"4","key":"10.1016\/j.bioorg.2018.09.018_b0215","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.plipres.2013.08.003","article-title":"Interaction of nonsteroidal anti-inflammatory drugs with membranes: in vitro assessment and relevance for their biological actions","volume":"52","author":"Pereira-Leite","year":"2013","journal-title":"Prog. Lipid Res."},{"issue":"2","key":"10.1016\/j.bioorg.2018.09.018_b0220","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jphs.2017.01.006","article-title":"Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1)","volume":"133","author":"Kongpracha","year":"2017","journal-title":"J. Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2018.09.018_b0225","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0006-8993(95)00012-F","article-title":"Localization of an isoform of carboxylesterase in rat brain differs from that in human brain","volume":"674","author":"Yamada","year":"1995","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.bioorg.2018.09.018_b0230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0014-5793(99)01111-4","article-title":"cDNA cloning, characterization and stable expression of novel human brain carboxylesterase","volume":"458","author":"Mori","year":"1999","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2018.09.018_b0235","first-page":"195","article-title":"Mammalian carboxylesterase 5: comparative biochemistry and genomics","volume":"3","author":"Holmes","year":"2008","journal-title":"Comp. Biochem. Physiol. Part D Genom. Proteom."},{"issue":"7","key":"10.1016\/j.bioorg.2018.09.018_b0240","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10709-010-9438-z","article-title":"Mammalian carboxylesterase 3: comparative genomics and proteomics","volume":"138","author":"Holmes","year":"2010","journal-title":"Genetica"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206818309131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206818309131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T14:45:42Z","timestamp":1565275542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206818309131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":48,"alternative-id":["S0045206818309131"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2018.09.018","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of human, rat and mouse hydrolyzing enzymes bioconverting amino acid ester prodrug of ketoprofen","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2018.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}